Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
compound lactobacillus acidophilus (Chongqing University Cancer Hospital)
- Development stage
- Unknown
- Lead developer
- Chongqing University Cancer Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Compound lactobacillus acidophilus is a multi-strain probiotic preparation typically containing *Lactobacillus acidophilus*, *Lactobacillus bulgaricus*, and *Streptococcus thermophilus*. It is primarily utilized in clinical practice to restore and maintain the balance of gastrointestinal microbiota. In the context of *Helicobacter pylori* infection, it is frequently employed as an adjunctive therapy alongside standard quadruple regimens (comprising a proton pump inhibitor, bismuth, and two antibiotics). The introduction of these beneficial bacteria helps to competitively inhibit *H. pylori* colonization, modulate the gastric immune response, and mitigate the gastrointestinal side effects commonly associated with intensive antibiotic treatment, thereby potentially improving overall eradication rates in patients with chronic gastritis or peptic ulcers.
- Brand names
- MeichangMeichang'an
- Other names
- Compound Lactobacillus Acidophilus TabletsFufang Shisuan Rushangan Pian
02
Targets
PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on compound lactobacillus acidophilus (Chongqing University Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on compound lactobacillus acidophilus (Chongqing University Cancer Hospital).